@Article {Luengo-Fernandez1801550，作者= {Luengo-Fernandez，Ramon和Penz，Erika和Dobson，Melissa和Psallidas，Ioannis和Nunn，Andrew J.和Maskell，Nick A.和Rahman，Najib M.}，标题= {胸腔感染组织纤溶酶原激活剂和DNase的成本效益：来自MIST2随机控制试验的证据}，体积= {54}，Number = {2}，Elocation-Id = {1801550}，年= {2019}，DOI = {10.1183 / 13993003.01550-2018}，出版商= {欧洲呼吸社会}188bet官网地址，摘要= {MIST2（第二多期胎儿脓毒症试验）试验表明，组织纤溶酶原激活剂（T-PA）和重组人DNase的组合使用组合使用与单一药剂或安慰剂相比是有效的。然而，治疗成本是显着的，结合治疗的总体成本效益仍然不清楚。举行迷雾剂试验的经济评估，以评估联合治疗的成本效益。包括与研究药物，初始住院住宿和随后住院有关的费用。结果是在获得的生命年份衡量的结果。所有费用均以欧元报告，2016年价格上涨.T-PA {\ TextEndash} DNASE集团的年费最低（T-PA为10欧元，1785欧元为DNASE，483欧元为安慰剂，7248欧元对于t-pa {\ textendash} dnase; p = 0.209）。用于T-Pa的平均1年预期寿命为0.988，DNA酶为0.923，适用于安慰剂和T-PA {TextEndash} DNase的0.969（P = 0.296）。 Both DNase and placebo were less effective, in terms of life-years gained, and more costly than t-PA. When placebo was compared with t-PA{\textendash}DNase, the incremental cost per life-year gained of placebo was EUR 1.6 billion, with a probability of 0.85 of t-PA{\textendash}DNase being cost-effective.This study demonstrates that combined t-PA{\textendash}DNase is likely to be highly cost-effective. In light of this evidence, a definitive trial designed to facilitate a thorough economic evaluation is warranted to provide further evidence on the cost-effectiveness of this promising combined intervention.The MIST2 trial showed that combined intrapleural use of t-PA and DNase was effective when compared with single agents or placebo in the treatment of pleural infection. This economic evaluation shows that t-PA{\textendash}DNase is likely to be highly cost-effective. bit.ly/2vYZhWt}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/54/2/1801550}, eprint = {//www.qdcxjkg.com/content/54/2/1801550.full.pdf}, journal = {European Respiratory Journal} }